The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S14-S19 , September 2007

Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment

  • Matthew R. Cooperberg

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceuticals.
    • ,
  • Jeannette M. Broering

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceuticals.
    • ,
  • Philip W. Kantoff

      Affiliations

    • Financial interest and/or other relationship with Abbott, Pfizer, Aventis, AstraZeneca, Bristol Myers Squibb, TAP Pharmaceuticals, Amgen, Novartis, Bayer, GlaxoSmithKline, Therion Biologies, Wilex, Genentech and Genzyme.
    • ,
  • Peter R. Carroll

      Affiliations

    • Corresponding Author InformationCorrespondence: University of California-San Francisco/Mt. Zion Cancer Center, 1600 Divisadero St., 3rd Floor, San Francisco, California 94115-1711 (telephone: 415-353-7098; FAX: 415-353-7093).
    • Financial interest and/or other relationship with National Institutes of Health/National Cancer Institute, Department of Defense, TAP Pharmaceuticals, InforMEDical and Strategic Education Physician Academy.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43
  2. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977
  3. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557
  4. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910
  5. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095
  6. D’Amico AV. Combined-modality staging in predicting prostate-specific antigen outcome after definitive local therapy for men with clinically localized prostate cancer. In: Prostate Cancer: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins; 2002;p. 254–268
  7. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006;98:355
  8. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24:46
  9. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141
  10. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, DuChane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938
  11. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. J Urol. 2004;171:1393
  12. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766
  13. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol. 2004;171:2255
  14. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006;107:2384
  15. Smith EB, Frierson HF, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?. Cancer. 2002;94:2282
  16. Terris MK. Prostate biopsy strategies: past, present, and future. Urol Clin North Am. 2002;29:
  17. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134
  18. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615
  19. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715

PII: S0022-5347(07)00823-3

doi: 10.1016/j.juro.2007.03.135

The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S14-S19 , September 2007

Article Tools

* Image Usage & Resolution